Last 33 quarters of trend data · Healthcare · Vaccines & Infectious Disease
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -13.43 | 33.66 | — | — | — | — | — | — | 26.38 | 36.66 | — | — | 14.34 | 39.36 | — | 15.34 | 4.25 | 4.83 | 5.78 | 2.99 | 5.29 |
| — | — | — | — | — | — | — | — | +83.9% | -6.9% | — | — | +237.2% | +714.8% | — | +412.3% | -19.6% | -12.6% | +11.2% | -51.8% | -61.1% | |
| P/S Ratio | 8.17 | 4.82 | 55.81 | 46.81 | 6.49 | 3.88 | 24.66 | 29.93 | 5.75 | 5.83 | 37.11 | 29.57 | 4.30 | 7.27 | 38.58 | 5.97 | 2.16 | 2.49 | 3.02 | 1.74 | 3.03 |
| — | +24.2% | +126.3% | +56.4% | +12.8% | -33.5% | -33.5% | +1.2% | +33.8% | -19.8% | -3.8% | +395.0% | +99.0% | +191.9% | +1176.2% | +243.9% | -28.6% | -14.5% | +10.8% | -49.3% | -79.0% | |
| P/B Ratio | 0.99 | 1.40 | 1.33 | 1.20 | 1.21 | 1.28 | 1.39 | 1.16 | 1.41 | 1.52 | 1.00 | 1.11 | 1.26 | 1.31 | 1.30 | 1.39 | 1.84 | 1.88 | 2.30 | 2.78 | 5.63 |
| — | +10.0% | -4.5% | +3.8% | -13.9% | -16.0% | +38.8% | +4.1% | +12.3% | +15.9% | -23.0% | -19.8% | -31.8% | -30.2% | -43.4% | -50.2% | -67.3% | -73.3% | -78.3% | -75.0% | -61.3% | |
| P/FCF | — | — | — | — | 24.55 | 7.27 | 9.19 | — | — | — | 2.97 | — | 5.56 | 9.86 | 1.59 | — | 13.50 | 1.84 | 2.51 | 2.78 | — |
| — | — | — | — | — | — | +209.2% | — | — | — | +87.3% | — | -58.8% | +437.2% | -36.9% | — | — | -84.9% | — | — | — | |
| EV / EBITDA | — | 8.22 | — | — | — | 44.43 | — | — | 14.23 | 89.56 | — | — | 5.78 | 27.86 | — | 6.40 | 1.75 | 2.20 | 3.29 | 2.00 | 3.47 |
| — | -81.5% | — | — | — | -50.4% | — | — | +146.1% | +221.5% | — | — | +229.6% | +1164.1% | — | +219.2% | -49.4% | -39.0% | -3.0% | -51.0% | -81.2% | |
| EV / EBIT | — | 16.31 | — | — | — | 136.85 | — | — | 14.94 | 29.49 | — | — | 9.28 | 13.89 | — | 5.96 | 1.84 | 2.18 | 3.18 | 1.91 | 3.48 |
| — | -88.1% | — | — | — | +364.0% | — | — | +61.0% | +112.3% | — | — | +405.8% | +537.5% | — | +212.4% | -47.2% | -40.6% | -10.7% | -54.3% | -86.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.6% | 92.0% | 8.1% | -63.2% | 63.3% | 90.2% | 70.7% | 54.2% | 79.5% | 85.6% | 53.5% | 68.5% | 87.9% | 81.9% | 2.9% | 92.5% | 95.7% | 78.3% | 76.1% | 79.7% | 89.5% |
| — | +1.9% | -88.5% | -216.6% | -20.5% | +5.4% | +32.1% | -20.9% | -9.5% | +4.5% | +1770.4% | -25.9% | -8.2% | +4.7% | -96.2% | +16.0% | +7.0% | -2.3% | -8.7% | -10.1% | +1.5% | |
| Operating Margin | -22.6% | 9.7% | -897.8% | -559.8% | -25.7% | -3.1% | -192.1% | -292.2% | 12.5% | 0.8% | -750.7% | -270.4% | 35.6% | 8.2% | -335.9% | 51.2% | 77.0% | 69.0% | 69.1% | 74.6% | 84.9% |
| — | +414.0% | -367.3% | -91.6% | -305.5% | -466.1% | +74.4% | -8.1% | -64.9% | -89.7% | -123.5% | -627.6% | -53.8% | -88.2% | -585.9% | -31.3% | -9.4% | -11.1% | -12.6% | -8.1% | +20.2% | |
| Net Margin | -39.6% | 14.3% | -777.3% | -450.4% | -33.6% | -1.9% | -148.2% | -227.5% | 21.8% | 15.9% | -627.7% | -168.0% | 31.0% | 17.9% | -113.5% | 39.3% | 53.3% | 51.6% | 52.3% | 58.0% | 57.2% |
| — | +857.4% | -424.3% | -98.0% | -254.1% | -111.9% | +76.4% | -35.4% | -29.6% | -11.3% | -452.8% | -527.1% | -41.9% | -65.2% | -317.1% | -32.2% | -6.9% | -2.2% | -0.4% | +5.4% | -46.1% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -5.7% | 1.0% | -4.5% | -2.9% | -1.6% | -0.2% | -2.1% | -2.2% | 1.3% | 1.0% | -4.1% | -1.6% | 2.3% | 0.8% | -0.9% | 2.4% | 11.9% | 10.1% | 10.2% | 26.6% | 28.8% |
| — | +770.5% | -117.9% | -31.4% | -219.0% | -115.0% | +50.1% | -38.4% | -41.0% | +28.5% | -355.6% | -165.6% | -80.8% | -92.0% | -108.9% | -91.0% | -58.8% | -75.4% | -85.3% | -54.1% | -9.8% | |
| ROA | -4.9% | 0.9% | -4.0% | -2.5% | -1.4% | -0.1% | -1.8% | -1.9% | 1.2% | 0.9% | -3.6% | -1.4% | 2.0% | 0.7% | -0.8% | 2.1% | 9.9% | 8.1% | 8.1% | 20.5% | 19.6% |
| — | +781.8% | -119.4% | -31.9% | -220.8% | -115.1% | +50.3% | -36.6% | -43.0% | +22.8% | -340.7% | -165.5% | -79.6% | -91.1% | -110.2% | -89.6% | -49.4% | -67.5% | -80.7% | -40.8% | +0.6% | |
| ROIC | -4.3% | 1.2% | -8.2% | -4.8% | -1.7% | -0.4% | -4.3% | -4.2% | 1.1% | 0.1% | -7.2% | -3.8% | 5.1% | 0.9% | -5.6% | 6.4% | 42.5% | 27.7% | 18.8% | 34.9% | 38.8% |
| — | +381.9% | -90.7% | -14.1% | -249.1% | -587.1% | +40.3% | -11.4% | -77.9% | -90.4% | -27.5% | -159.8% | -87.9% | -96.8% | -130.0% | -81.8% | +9.6% | -51.3% | -80.0% | -68.0% | -46.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 |
| — | +53.0% | +22.2% | +4.6% | +6.2% | +4.2% | +9.1% | +30.8% | +21.0% | +25.4% | +29.2% | +14.3% | +2.3% | -31.9% | -27.2% | -11.4% | -58.3% | -54.7% | -69.7% | -88.4% | -85.5% | |
| Debt / EBITDA | — | 0.79 | — | — | — | 3.17 | — | — | 0.81 | 4.44 | — | — | 0.36 | 1.76 | — | 0.33 | 0.06 | 0.11 | 0.11 | 0.04 | 0.06 |
| — | -75.2% | — | — | — | -28.5% | — | — | +123.5% | +151.5% | — | — | +466.9% | +1459.4% | — | +754.2% | +0.1% | +61.6% | +74.8% | -74.4% | -93.2% | |
| Current Ratio | 7.54 | 8.55 | 7.85 | 8.80 | 7.54 | 7.12 | 8.61 | 10.18 | 7.45 | 7.33 | 7.54 | 11.38 | 9.43 | 10.37 | 10.56 | 12.95 | 7.43 | 5.37 | 5.15 | 5.05 | 4.33 |
| — | +20.1% | -8.8% | -13.6% | +1.1% | -2.8% | +14.2% | -10.5% | -21.0% | -29.4% | -28.7% | -12.1% | +26.9% | +93.1% | +105.1% | +156.4% | +71.6% | +95.1% | +93.0% | +87.3% | +57.4% | |
| Quick Ratio | 7.49 | 8.52 | 7.80 | 8.74 | 7.49 | 7.02 | 8.48 | 10.02 | 7.34 | 7.21 | 7.40 | 11.16 | 9.26 | 10.14 | 10.32 | 12.68 | 7.28 | 5.30 | 5.06 | 4.93 | 4.18 |
| — | +21.3% | -8.1% | -12.7% | +2.0% | -2.6% | +14.7% | -10.3% | -20.7% | -28.9% | -28.3% | -11.9% | +27.2% | +91.4% | +104.0% | +157.1% | +74.0% | +98.2% | +96.6% | +90.8% | +58.2% | |
| Interest Coverage | -73.00 | 27.75 | -107.70 | -141.03 | -33.98 | 62.89 | -121.29 | -66.13 | — | 31.98 | -109.58 | -68.91 | 19.88 | 111.18 | -316.75 | 622.24 | 1511.76 | 552.40 | 394.12 | 740.11 | 2228.30 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 33 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BNTX stock.
BioNTech SE's current P/E is -13.4x. The average P/E over the last 1 quarters is 33.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BioNTech SE's current operating margin is -22.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioNTech SE's business trajectory between earnings reports.